These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23881439)

  • 21. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial.
    Kobayashi N; Inaba Y; Uchiyama M; Ike H; Kubota S; Saito T
    J Arthroplasty; 2016 Jan; 31(1):333-8. PubMed ID: 26260784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.
    Bauer DC; Schwartz A; Palermo L; Cauley J; Hochberg M; Santora A; Cummings SR; Black DM
    JAMA Intern Med; 2014 Jul; 174(7):1126-34. PubMed ID: 24798675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial.
    Morita A; Kobayashi N; Choe H; Ike H; Tezuka T; Higashihira S; Inaba Y
    J Orthop Surg Res; 2020 Jan; 15(1):17. PubMed ID: 31948455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cartilage degradation marker, urinary CTX-II, is associated with the risk of incident total joint replacement in postmenopausal women. A 18 year evaluation of the OFELY prospective cohort.
    Garnero P; Sornay-Rendu E; Chapurlat R
    Osteoarthritis Cartilage; 2020 Apr; 28(4):468-474. PubMed ID: 31982562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.
    Arabmotlagh M; Pilz M; Warzecha J; Rauschmann M
    J Orthop Res; 2009 Feb; 27(2):183-8. PubMed ID: 18752281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
    Omidvar B; Ghorbani A; Shahbazian H; Beladi Mousavi SS; Shariat Nabavi SJ; Alasti M
    Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
    Yoshioka T; Okimoto N; Okamoto K; Sakai A
    J Bone Miner Metab; 2013 Mar; 31(2):153-60. PubMed ID: 23076293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F
    J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
    Finkelstein JS; Leder BZ; Burnett SM; Wyland JJ; Lee H; de la Paz AV; Gibson K; Neer RM
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.
    Bingham CO; Buckland-Wright JC; Garnero P; Cohen SB; Dougados M; Adami S; Clauw DJ; Spector TD; Pelletier JP; Raynauld JP; Strand V; Simon LS; Meyer JM; Cline GA; Beary JF
    Arthritis Rheum; 2006 Nov; 54(11):3494-507. PubMed ID: 17075851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
    Baxter I; Rogers A; Eastell R; Peel N
    Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.